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Scientists world\vide are striving without heed in order 
to develop new vaccines which protect the human race 
against old and emerging diseases. 
However it is not only the menu of these vaccine preventable 
diseases which is being extended but the quality and efficacy 
of these vaccines are improving tremendously. Researchers 
are today studying vaccine adjuvants which improve the 
immunogenicity of the product, aiming to create a vaccine 
which provides lifelong immunity and which is well tolerated 
and free from side effects. The problem of the pin cushion 
effect with multiple injections during one and subsequent 
visits to the family doctor and pediatrician will soon be a thing 
of the past with the introduction of combination vaccines. 
Also in the twenty first century the use of edible vaccines , 
nasal sprays or skin lotions may eliminate the use of needles 
completely. 
The following information will focus on three novel vaccines 
which should be stocked in pharmacies in Malta and Gozo 
in the very near future. These vaccines are against (1) Rotavirus, 
a common cause of gastroenteritis in children, (2) Human 
Papilloma Virus (HPV) which may lead to carcinoma of the 
cervix and (3) Malaria, a parasitic disease which kills more 
than one million people every year. 
Rotavirus 
The Rotavirus vaccines are a new generation of vaccines 
which are fast making their way into our clinics. These are 
already licensed in some countries and have been given the 
go ahead by the European Medicines Agency (EMEA). 
These live attenuated vaccines will provide lasting protection 
when given in two doses as an oral preparation, with the 
first dose given at six weeks and the second dose given 
14 weeks later. These new vaccines are not associated with 
episodes of intussusceptions, which had caused the only 
US-licensed rotavirus vaccine to be removed from the market 
in 1999. The three currently registered rotavirus vaccines 
are the Rotarix'" (GSK), RotashieldT" (Wyeth/Biovirx) and 
LLRHI (Lanzhon Institute of Biological Products, China) . 
Rotateq (MSD) is in its phase III trials and is just about to 
be registered. 
Human Papilloma Virus (HPV) Vaccines 
HPV-Deoxy Ribo Nucleic Acid (DNA) is present in 90-100 
% of carcinoma of the cervix, with the most common HPV 
types being HPV 16 and 18. It is now well established that 
HPV is the leading cause of carcinoma of the cervix and the 
progression may take years or even decades, and it may even 
regress spontaneously. 
Table 1: Basic table of main HPV types and the associated lesions. 
Lesion 
Plantar warts 
Hand warts 
Genital warts 
Cervical carcinoma 
HPV type 
1,2,4 
2,4 
6,11 
16,18,31.45 
